If a patient with acute kidney injury is receiving ACE inhibitors, the nurse should cautiously monitor for:

NHM UP Staff Nurse - 2019

Medical & Surgical Nursing

Hard

Appeared in: NHM UP Staff Nurse - 2019

Explanation

ACE inhibitors prevent the formation of angiotensin II, a substance that constricts blood vessels and stimulates the release of aldosterone.
Aldosterone is a hormone responsible for promoting sodium reabsorption and potassium excretion by the kidneys.
By inhibiting aldosterone release, ACE inhibitors cause the body to retain potassium.
In Acute Kidney Injury (AKI), the kidneys are already failing to excrete potassium effectively.
The combined effect of the drug (potassium retention) and the disease (impaired potassium excretion) creates a high risk for severe hyperkalemia (abnormally high serum potassium).
Hyperkalemia is a serious condition that can lead to life-threatening cardiac arrhythmias.

Option B: While serum phosphate levels are often elevated in AKI due to decreased renal excretion, this is not a direct or primary effect of ACE inhibitors. The drug's mechanism does not specifically target phosphate regulation.
Option C: Serum magnesium levels can also be elevated in AKI because the kidneys are the primary route of magnesium excretion. However, ACE inhibitors do not have a primary effect on magnesium balance, unlike their significant impact on potassium.
Option D: Serum copper level is not routinely monitored in the context of AKI or ACE inhibitor therapy. It is not an electrolyte that is primarily regulated by the kidneys in a way that is acutely affected by this drug-disease combination.

Clinical Relevance

Nursing practice connection: Use the key finding related to The primary electrolyte imbalance to monitor when administering ACE inhibitors to a patient with acute kidney injury to guide bedside assessment, documentation, and the next nursing action.
A nurse's primary responsibility is patient safety. Recognizing the high risk of hyperkalemia from this common drug-disease interaction is critical to prevent cardiac arrest.
Nurses must monitor lab values, especially potassium, before and after administering ACE inhibitors to patients with any degree of renal impairment.
Patient education is key. The nurse should teach the patient and family about the signs of hyperkalemia and the importance of avoiding potassium-rich foods and salt substitutes (which often contain potassium chloride).

How to Approach the Question

First, identify the key elements in the question: the patient's condition is 'acute kidney injury' (AKI), and the medication is an 'ACE inhibitor'.
Recall the pathophysiology of AKI. The primary problem is the kidneys' reduced ability to filter waste and maintain electrolyte balance, including excreting potassium.
Next, recall the mechanism of action of ACE inhibitors. They block the RAAS pathway, which leads to lower aldosterone levels.
Connect the drug's effect to electrolyte balance. Remember that aldosterone's job is to get rid of potassium. Therefore, less aldosterone means more potassium stays in the body.
Synthesize the two points: The patient's body can't get rid of potassium because of AKI, and the drug is making the body hold on to even more potassium.
Conclude that the most significant and immediate risk is a dangerously high potassium level (hyperkalemia).

Concept Tested & Keywords

Concept Tested: The primary electrolyte imbalance to monitor when administering ACE inhibitors to a patient with acute kidney injury.
Stem keywords: acute kidney injury, ACE inhibitors, monitor
Lead-in keywords: cautiously monitor for
Clinical cues: The combination of a specific disease (AKI) and a drug class (ACE inhibitor) points to a potential drug-disease interaction.

QlKG33x3cD7UGSHe-sBtxm

E6 Medicine Davidson Principles Practice 24e p. 380-382

E6 Nursing Brunner Adult Health 3SA Vol 1 Part 1 p. 149-151

E6 Nelson Textbook of Pediatrics(2024) — Volume 2 p. 1048-1050